Upload
trinhcong
View
220
Download
0
Embed Size (px)
Citation preview
Disclaimer The information contained in this confidential document ("Presentation") has been prepared by CHC Healthcare Group (the "Company"). It has not been fully verified
and is subject to material updating, revision and further amendment.
While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or
advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or
completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any
interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the
Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or
indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions
contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.
Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any
transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be
responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company
does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any
inaccuracies in, or omissions from, this Presentation which may become apparent.
This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or
advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and
taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of
subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of
historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company
believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future
performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ
materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially
from those projected in forward-looking statements.
1
Swissray Global Healthcare Holding Ltd. (4198)
Institutional Investor Conference
Gilbert Wai, CEO
2016 Dec. 15th
Swissray Medical AG Mfg/Sales&Service
Swissray International Inc. R&D/Mfg/Sales&Service
Swissray Asia Healthcare Co. Ltd.
Sales&Service
Swissray Global Healthcare Holding Ltd.
(4198) Headquarter
SMTH AG Holding Co.
Founded in 2013 Listed on Dec. 23, 2014
Founded in 2009
Founded in 1988 Founded in 2002 Founded in 2011
100%
100% 100% 100%
New Jersey, USA Wisconsin, USA Taipei, Taiwan Hochdorf, Switzerland 3
Company Organizational Structure
Founded in 2015
Swissray Healthcare Holding (H.K.) Ltd.
Global Network Channels
4
China Taiwan Hong Kong Thailand Australia New Zealand
USA Brazil Costa Rica Jamaica Columbia
Switzerland Germany Austria France Netherlands Belgium
1 4
3 5
2
7
9
8
6
Russia Romania Czech Iran UAE Egypt
EMEA
APAC Americas
Philippines Vietnam Singapore Indonesia Malaysia Myanmar
Europe, Middle East, Africa Asia, Oceania, Greater China North America, South America
Current Product Line (1/5)
5
Surgical Products
Novadaq
Bone Health Products
Norland
X-ray Products
Swissray
6
Current Product Line (2/5)
ddRAura – released to the market in 2016
7
Set up demo site at Tower Radiology & Breast Center in October 2016
• Smarter Technology for Smoother Workflow • A Comprehensive System for More Versatility • Total System Automation for Ultimate
Workflow Efficiency • Different Configurations for Different
Requirements • Advance and Affordable Workflow Redefined • A User Interface with a Difference • Single Focus Stitching for Higher Accuracy
Current Product Line (3/5)
ddRAura™OTC
ddRAura™OTC APS
ddRAura™FMTS
Norland: Bone densitometer
8
Norland Elite Target to the bariatric and athletic
markets
Norland XR-800
Norland XR-600
Current Product Line (4/5)
Novadaq: Real Time Fluorescence Image System
9
Current Product Line (5/5)
First SPY Case in Kuala Lumpur Hospital in Malaysia PinPoint well received at Rajavithi Hospital in Thailand
Distributor in Vietnam: Schmidt Biomedtech Japanese scholar promoting in International Conference
10
SR Pulse 710 1.5T Wide-Bore Magnetic Resonance Imaging
MRI Market Analysis (1/4)
11
2016 VS 2021
Source: MarketsandMarkets, 2016
Global MRI market reached to US$ 5.6 billion in 2016 Expected to be approximately US$ 7.2 billion by 2021
Compound annual growth rate of 5.1%
12 Source: MarketsandMarkets, 2016
SHARE OF THE MRI SYSTEMS MARKET IN 2021
1.5T High-field MRI accounts for more than 45% of total MRI market
MRI Market Analysis (2/4)
MRI Market Analysis (3/4)
13
GEOGRAPHICAL SNAPSHOT: 2015
Source: MarketsandMarkets, 2016
North America market accounts for 31.4% of the global market- the largest market for MRI
MRI Market Analysis (4/4)
14
“The closed MRI systems segment is the fastest-growing segment of the MRI systems market. The high growth rate of this segment is attributed to the ongoing focus on replacement of narrow-bore (60 cm) closed MRI scanners with wide-bore (70 cm) closed MRI scanners. “
Source: MarketsandMarkets, 2016
SR Pulse 710 Magnetic Resonance Imaging
15
1.5T, 710 mm Wide-Bore High
Performance
State-of-the-Art Features
Cryogen Zero Boil-off
Made in USA
Market price of similar products US$ 1.1-1.5 million
16
SR Pulse 710 Total Cost of Ownership
Fastest Break Even Potential
Fastest ROI
* MD buyline comparison of 1.5T Wide-Bore systems 8/2015- 8/2016
Swissray SR Pulse 710 Swissray SR Pulse 710
Radiological Society of North America (1/5)
17
RSNA Theme: BEYOND IMAGING Swissray’s Theme: BEYOND DR
November 27 - December 2, 2016 @ Chicago
Radiological Society of North America (2/5)
18
19
Radiological Society of North America (3/5)
Radiological Society of North America (4/5)
20
Radiological Society of North America (5/5)
21
22
SR Pulse 710 - Publication in Diagnostic Imaging Europe
ddRAura - Publication in Diagnostic Imaging Europe
23
24
Ionizing Radiation X-ray / Norland DXA
Imaging Diagnostic MRI/ Ultrasound/ CT
Radiation Therapy
Hig
he
r V
alu
e
Product Expansion Strategy
SR Pulse 710
Beyond DR ddR series Future
Digital X-ray
ddRFormula ddRElement ddRVersa ddRCruze ddRAura FMTS ddRAura OTC ddRImpulse …
Diagnosis Imaging
MRI Ultrasound CT PET/CT … DXA (2013) Novadaq (2013)
Radiation Therapy
Radiotherapy System
2016 2017-2018 2019-2020
Thank you for your time.
25